Lipella completes Phase 2a trial of LP-10 for hemorrhagic cystitis; reports $5.1M cash, IPO completed

LIPELLA PHARMACEUTICALS INC.

Completed Phase 2a trial of LP-10 for hemorrhagic cystitis; top-line results showed no serious adverse events and reduced symptoms.
Year-end cash $5.1M, provides operating runway into 2024.
Appointed Douglas Johnston as CFO in November 2022.
Completed IPO and Nasdaq listing in December 2022.
Created Oral Health Scientific Advisory Board for LP-310; results to be presented at AUA meeting April 30, 2023.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

LIPELLA PHARMACEUTICALS INC. reported financial results for the fiscal year ended December 31, 2022.

Period: the fiscal year ended December 31, 2022
Result: reported results

Exact text from the filing

today provided a business update and reported financial results for the year ended December 31, 2022.

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

LIPELLA PHARMACEUTICALS INC. filing history →

Source: SEC EDGAR

accession 0001753926-23-000382

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.